Board Certification: Clinical Cardiac Electrophysiology, American Board of Internal Medicine (2013)
Fellowship: Stanford University (2012) CA
Board Certification: Cardiovascular Disease, American Board of Internal Medicine (2011)
Fellowship, Stanford University Hospital, Cardiovascular Medicine (2010)
Board Certification: Internal Medicine, American Board of Internal Medicine (2006)
Residency: Stanford University Hospital -Internal Medicine Residency Training Program (2006) CA
Medical Education: New York University - School Of Medicine (2003) NY
BA, Harvard University (Cognitive Neuroscience), MA (1998)
Honors & Awards
F32 Ruth L. Kirschstein National Research Service Award, NIH (07/2009-06/2011)
Postdoctoral Fellowship Award (deferred), American Heart Association, Western States Affiliate (07/2009-06/2011)
Outstanding Clinical Fellow - Cardiovascular Medicine, Stanford University Medical Center (2009)
Chief Fellow - Cardiovascular Medicine, Stanford University Medical Center (2009-2010)
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Pacemaker Therapy in Atrial Fibrillation
Park, S., Wang, P. J., Zei, P. C., Hsia, H. H., Turakhia, M., & Al-Ahmad, A. (2013). Pacemaker Therapy in Atrial Fibrillation. Journal of Cardiology and Vascular Medicine, 1.
Shirley Park & Euan Ashley, Reza Ardehali, Paul J. Wang, Marco Perez (eds, & ). (2011). Hemodynamic Monitoring. A Practical Approach to Cardiovascular Medicine.
Optical Control of Cardiomyocyte Depolarization and Inhibition Utilizing Channelrhodopsin-2 (ChR2) and a Third Generation Halorhodopsin (eNpHR3.0)
Shirley Park, Ragu Vijaykumar, Paul G. Yock, Paul J. Wang, & Karl Deisseroth. (2010). Optical Control of Cardiomyocyte Depolarization and Inhibition Utilizing Channelrhodopsin-2 (ChR2) and a Third Generation Halorhodopsin (eNpHR3.0). Circulation, 122(21).
Two Hsp70 family members expressed in atherosclerotic lesions
Han, Z. H., Truong, Q. A., Park, S., & Breslow, J. L. (2003). Two Hsp70 family members expressed in atherosclerotic lesions. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 100(3), 1256-1261.